And more talk of our favourite product AOD9086. Very confidant reply. These are ESRAS words....
( The best application of this particular technology is obviously skin care where you do want to deliver your anti-ageing products, your anti-cellulite products to the skin)
"DR ESRA OGRU : It's totally topical and it's a multi-component system without going into too much science, but it can be formulated in such a way that actives can be delivered into the skin, so topically, or into the blood, systemically. There's a lot of knowhow and a lot of fantastic science that's behind this, so by regulating TPM and the TPM ratio and the active ratio, we can actually deliver actives into the skin. The best application of this particular technology is obviously skin care where you do want to deliver your anti-ageing products, your anti-cellulite products to the skin, not in the blood. It's in the skin where all the action is happening and this is exactly what we're doing with our cosmetic line.
DESLEY BLANCH : And why is skin care -- on the financial side of managing the business?
DR ESRA OGRU : It's very attractive, it's a nice business, short term returns, increased company profile and I suppose when we sat down we thought, well, we can go out and partner this, but at the same time, we can leverage on the fantastic science that we've developed over the years and actually go out there and market a product and return great value to our investors at the end of the day. We're a listed company, we want the TPM profile to be out there, and we want to give back at the same time.
- Forums
- ASX - By Stock
- AVE
- oxycodone trials
AVE
avecho biotechnology limited
Add to My Watchlist
12.5%
!
0.4¢

oxycodone trials, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.10M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $453 | 129.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
40 | 33486086 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 8328117 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
40 | 33486086 | 0.003 |
15 | 16879866 | 0.002 |
15 | 57221222 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 8328117 | 7 |
0.005 | 13262502 | 18 |
0.006 | 31623747 | 5 |
0.007 | 4498187 | 12 |
0.008 | 4722624 | 6 |
Last trade - 13.52pm 04/07/2025 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online